Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) | RFA AR 17 009

Opportunity Information: Apply for RFA AR 17 009

The Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) funding opportunity (RFA-AR-17-009) is a National Institutes of Health (NIH) initiative run through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). It is designed to push musculoskeletal research in directions that most traditional NIH mechanisms tend to avoid. The central purpose is to fund bold, unconventional ideas that could shift how the field thinks about musculoskeletal diseases, even when the preliminary evidence base is thin or the approach is considered controversial. In practice, this means NIAMS is explicitly inviting applicants to bring forward projects based on unusual observations, imaginative hypotheses, and creative concepts that challenge prevailing theories or standard practices, with the goal of building new paradigms rather than incrementally extending existing ones.

A defining feature of this opportunity is its emphasis on "high risk, high reward" science within the NIAMS mission space. The FOA is meant for projects that reviewers might otherwise label as too risky, too early-stage, too speculative, or too unconventional for standard grant programs. The intent is not to fund routine confirmatory studies, but rather to back research that could open up entirely new scientific and translational paths in musculoskeletal disease. While the FOA frames this as innovation for scientific knowledge, it also makes clear that the work should remain relevant to musculoskeletal diseases and aligned with NIAMS priorities.

In terms of project scope, the FOA intends to support disease-focused translational research that advances toward practical application, but stops short of first-in-human testing. The studies can move along the translational pipeline up to, but not including, initial human trials. Just as importantly, the opportunity is not meant to support clinical trials, so applicants should not propose trial designs or clinical trial-like activities under this mechanism. In other words, the program is positioned to help investigators generate the critical evidence, tools, or proof-of-concept data that could justify later-stage translational steps, but without crossing into clinical trial territory.

The mechanism is an R61/R33, which is commonly used by NIH to support phased innovation: an early, exploratory or high-risk phase (R61) followed by a second phase (R33) intended for continued development once early milestones are met. Even without the FOA text describing milestone details, the structure signals that NIAMS expects applicants to propose a plan where initial feasibility or key proof-of-concept questions are addressed first, and then, if successful, the project transitions into a more developed stage of research. This structure is especially well-suited to unconventional ideas because it allows the agency to support risky starts while still requiring a clear path to meaningful progress.

Eligibility is broad across many U.S.-based organization types. Eligible applicants include various levels of government (state, county, city or township, and special district governments), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized. The FOA also allows public housing authorities/Indian housing authorities, nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those nonprofit categories), for-profit organizations other than small businesses, and small businesses. It also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. Taken together, this reflects an intent to draw in a diverse range of research performers and community-connected entities that can contribute to musculoskeletal innovation.

At the same time, the FOA places strict limits on foreign involvement. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply. In addition, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. This effectively confines applicant organizations and project components to the United States and its eligible jurisdictions.

From the administrative details provided, this is a discretionary grant opportunity in the health funding activity category, listed under CFDA 93.846. The opportunity was created on 2016-08-01, with an original closing date of 2017-07-10. The listed award ceiling is $250,000, indicating an upper limit on the amount that can be awarded under the terms summarized here (though actual budgets in NIH awards are typically shaped by the FOA, project needs, and NIH policies). The expected number of awards is not specified in the provided text.

Overall, this RISK (R61/R33) opportunity is best understood as NIAMS making room for scientifically credible but nontraditional musculoskeletal disease research that might otherwise struggle to find support because it does not fit mainstream assumptions, lacks extensive preliminary data, or challenges established frameworks. It is meant to help investigators transform provocative observations and daring hypotheses into testable, translationally relevant evidence, while staying preclinical or pre-first-in-human and avoiding clinical trial activities.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Research Innovations for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2016-08-01.
• Applicants must submit their applications by 2017-07-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $250,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 17 009

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: